These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9764934)

  • 1. Financing HIV service provision in England: estimated impact of the cost of antiretroviral combination therapy.
    Beck EJ; Tolley K
    Int J STD AIDS; 1998 Sep; 9(9):512-7. PubMed ID: 9764934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
    Int J STD AIDS; 1999 Jun; 10(6):357-62. PubMed ID: 10414877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect cost of HIV infection in England.
    Mullins CD; Whitelaw G; Cooke JL; Beck EJ
    Clin Ther; 2000 Nov; 22(11):1333-45. PubMed ID: 11117658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the cost of getting the price wrong?
    Beck EJ; Beecham J; Mandalia S; Griffith R; Walters MD; Boulton M; Miller DL
    J Public Health Med; 1999 Sep; 21(3):311-7. PubMed ID: 10528959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre.
    Beck EJ; Mandalia S; Griffith R; Beecham J; Walters MD; Boulton M; Miller DL
    Pharmacoeconomics; 2000 Jan; 17(1):53-69. PubMed ID: 10747765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use and cost of HIV service provision in England in 1996. National Prospective Monitoring System (NPMS) Steering Group and NPMS Working Party on Costs.
    Beck EJ; Tolley K; Power A; Mandalia S; Rutter P; Izumi J; Beecham J; Gray A; Barlow D; Easterbrook P; Fisher M; Innes J; Kinghorn G; Mandel B; Pozniak A; Tang A; Tomlinson D; Williams I
    Pharmacoeconomics; 1998 Dec; 14(6):639-52. PubMed ID: 10346416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the costs of paediatric HIV infection and AIDS: comparison of infected children born to screened and unscreened mothers.
    Sculpher MJ; Gibb D; Ades AE; Ratcliffe J; Duong T
    AIDS; 1998 Jul; 12(11):1371-80. PubMed ID: 9708418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
    Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
    PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative estimates of the financial burden to the UK health system of hospital care for people with and without diabetes in the year before death.
    Currie CJ; Morgan CL; Dixon S; McEwan P; Marchant N; Bearne A; Sharplin P; Peters JR
    Diabetes Res Clin Pract; 2004 Sep; 65(3):267-74. PubMed ID: 15331207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between smoking during pregnancy and hospital inpatient costs in childhood.
    Petrou S; Hockley C; Mehta Z; Goldacre M
    Soc Sci Med; 2005 Mar; 60(5):1071-85. PubMed ID: 15589675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financial cost of social exclusion: follow up study of antisocial children into adulthood.
    Scott S; Knapp M; Henderson J; Maughan B
    BMJ; 2001 Jul; 323(7306):191. PubMed ID: 11473907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One world, one hope: the cost of providing antiretroviral therapy to all nations.
    Hogg RS; Weber AE; Craib KJ; Anis AH; O'Shaughnessy MV; Schechter MT; Montaner JS
    AIDS; 1998 Nov; 12(16):2203-9. PubMed ID: 9833862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shoulder acute pain in primary health care: is retraining GPs effective? The SAPPHIRE randomized trial: a cost-effectiveness analysis.
    McKenna C; Bojke L; Manca A; Adebajo A; Dickson J; Helliwell P; Morton V; Russell I; Torgerson D; Watson J
    Rheumatology (Oxford); 2009 May; 48(5):558-63. PubMed ID: 19258378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.
    Lacey L; Youle M; Trueman P; Staszewski S; Schrappe M; Behrens M
    Pharmacoeconomics; 1999; 15 Suppl 1():39-53. PubMed ID: 10537441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.
    Maslove L; Gower N; Spiro S; Rudd R; Stephens R; West P
    Thorax; 2005 Jul; 60(7):564-9. PubMed ID: 15994264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy.
    Anis AH; Hogg RS; Wang XH; Yip B; Palepu A; Montaner JS; O'Shaughnessy MV; Schechter MT
    Pharmacoeconomics; 1998 Jun; 13(6):697-705. PubMed ID: 10179705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between TISS and ICU cost.
    Dickie H; Vedio A; Dundas R; Treacher DF; Leach RM
    Intensive Care Med; 1998 Oct; 24(10):1009-17. PubMed ID: 9840233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness in the management of patients with oesophageal cancer.
    Farndon MA; Wayman J; Clague MB; Griffin SM
    Br J Surg; 1998 Oct; 85(10):1394-8. PubMed ID: 9782023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial.
    Petrou S; Bischof M; Bennett C; Elbourne D; Field D; McNally H
    Pediatrics; 2006 May; 117(5):1640-9. PubMed ID: 16651318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost effectiveness analysis of goserelin compared with danazol as endometrial thinning agents.
    Sculpher M; Thompson E; Brown J; Garry R
    BJOG; 2000 Mar; 107(3):340-6. PubMed ID: 10740330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.